Sudden Reversal of Semaglutide Pill Launch

In a dramatic about-face, telehealth provider Hims & Hers has canceled its plans to offer a lower-cost alternative to Novo Nordisk’s Wegovy pill. The company announced the reversal just two days after revealing its compounded semaglutide pill would be priced at $49 for the first month and $99 monthly thereafter – approximately $100 less than Wegovy.

Legal Pressure Forces Immediate Retreat

Novo Nordisk’s Legal Threats

Danish pharmaceutical giant Novo Nordisk swiftly responded to Hims & Hers’ announcement with a legal threat. The Wegovy manufacturer condemned the proposed product as “an unapproved, inauthentic, and untested knockoff” of semaglutide, the active ingredient in Wegovy. Novo Nordisk asserted it would take “legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework.”

FDA’s Regulatory Intervention

The U.S. Food and Drug Administration (FDA) amplified pressure on Friday by announcing restrictions on GLP-1 ingredients like semaglutide in non-approved compounded drugs. The agency specifically targeted the business model used by telehealth providers marketing alternatives to FDA-approved weight loss medications.

- Advertisement -

Company’s Official Statement

Facing this regulatory and legal pressure, Hims & Hers announced on social media: “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.”

Market Context and Weight Loss Drug Boom

GLP-1 Market Expansion

This reversal occurs amid explosive growth in the GLP-1 weight loss drug market. Spending on GLP-1 medications increased by over 500% between 2018-2023, soaring from $13.7 billion to $71.7 billion according to the American Medical Association. The market’s expansion follows Wegovy’s FDA approval as the first daily oral GLP-1 pill.

Super Bowl Advertising Blitz

The controversy unfolded during a major advertising push by weight loss companies during Super Bowl LVIII. Hims & Hers aired a commercial addressing America’s “health gap,” while competitors Ro (featuring Serena Williams) and Wegovy (with Kenan Thompson) also debuted high-profile ads. This marketing frenzy highlights the commercial significance of the weight loss drug market.

Compounded Alternatives vs. FDA-Approved Drugs

While abandoning the semaglutide pill, Hims & Hers continues selling GLP-1 injections, historically the primary delivery method for these medications. The telehealth sector has marketed compounded alternatives as affordable solutions to expensive FDA-approved treatments. However, compounded drugs bypass FDA quality controls, raising concerns about potency consistency and patient safety.